Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AAV2hAQP1 Gene Therapy for Radiation-Induced Parotid Salivary Hypofunction
NCT02446249Phase 1Completed
- Sponsor
- MeiraGTx
- Start
- May 2015
- Primary completion
- Aug 2026
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AAV-AQP1 in radiation-induced xerostomia and salivary hypofunction, sponsored by MeiraGTx. Primary endpoint: Safety of vector at 36 months. Started May 2015; status: completed.
02
Drugs
AAV-AQP1
03
Conditions
radiation-induced xerostomiasalivary hypofunction
Beyond the preview
Go deeper on NCT02446249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02446249.